Management of High And Very High Risk Patients with Hyperlipidaemia in Israel: An Observational Study

Aim: A multi-country observational study was conducted between May 2016-August 2017 to explore the current management of elevated LDL-C in high-risk (HR) and very high-risk (VHR) patients across central/eastern Europe. Here we present data from the Israeli subset of the study.

Methods: Adult patients with ≥2 clinic visits, ≥2 LDL-C measurements and valid lipid-modifying therapy (LMT) documentation were enrolled at 9 sites (including academic/specialist/GP centres) throughout Israel. Data were collected from patient medical records, for the 12 months before enrolment.

Results: The study enrolled 193 patients, mean (SD) age 65.9 (11.0) years. This included 32 patients with familial hypercholesterolaemia (FH); 88 with diabetes; 26 with STEMI and 156 receiving LMT as secondary prevention: 20 were classified as HR and 173 as VHR, as defined by ESC/EAS guidelines. Time since diagnosis was ≥ 5 years in 98 patients (50.8%). Almost all patients (184/193; 95.3%) were receiving statins, either alone (105: 54.4%) or in combination (79: 40.9%); 69 (35.8%) were receiving high-intensity statins. A total of 72 patients were receiving ezetimibe, mostly as combination therapy (n=69; 35.8%). Mean LDL-C at first and last observation was 102.86 ± 54.91 mg/dL and 88.94 ± 42.15 mg/dL, respectively, with 9 (45%; 95% CI 23.1-68.5%) HR patients achieving

Conclusions: Our findings are consistent with previous reports that a large proportion of patients with hyperlipidaemia, particularly those with FH, are undertreated and do not achieve ESC/EAS defined LDL-C targets.